Last update 11 Jul 2024

Ketorolac Tromethamine

Overview

Basic Info

SummaryKetorolac Tromethamine, also known by its trade name Toradol®, is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for the treatment of moderate to severe pain, including pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders, and headaches. Developed and approved by Roche in 1989, Ketorolac Tromethamine functions as a COX inhibitor, effectively reducing pain by blocking the production of prostaglandins. This medication is available in both oral and injectable formulations, making it a versatile option for pain management. Despite its effectiveness, Ketorolac Tromethamine is not recommended for long-term use due to its potential side effects, including gastrointestinal bleeding and kidney damage.
Drug Type
Small molecule drug
Synonyms
Acular
+ [14]
Mechanism
COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors)
Active Indication
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (30 Nov 1989),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC19H24N2O6
InChIKeyBWHLPLXXIDYSNW-UHFFFAOYSA-N
CAS Registry74103-07-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pain
US
14 May 2010
Inflammation
US
22 Jul 2009
Burns
US
30 May 2003
Eye Pain
US
30 May 2003
Acute Pain
CN
-14 Mar 2001
Conjunctivitis, Allergic
CN
17 Sep 1999
Post procedural inflammation
US
09 Nov 1992
Seasonal allergic conjunctivitis
US
09 Nov 1992
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Back PainPhase 1-01 Mar 2013
ToothachePhase 1
CN
12 Jul 2007
Migraine DisordersPhase 1
DE
01 Jul 2007
Pain, PostoperativePhase 1
NZ
01 Jun 2003
PainPhase 1
US
30 Nov 1989
Tooth, ImpactedPreclinical
US
01 Feb 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
70
(Post-Operative Non Opioid Pain Protocol)
cezeiiqdwo(hqbsyeenhe) = gkwiteeqjl hwbzixlpog (ktwamwygqh, xvfkpiqfux - leikglqsjp)
-
02 Apr 2024
(Post-Operative Traditional Pain Protocol)
cezeiiqdwo(hqbsyeenhe) = qkdglaewcm hwbzixlpog (ktwamwygqh, kpktdkkczz - dwffuxnyms)
Phase 3
119
dsikerbfvu(jtqxwxfnqi) = txgmustlgi qchzyjiooh (suvevdttmf, kwerrnlxct - pmnsrwnylh)
-
18 Dec 2023
Oxycodone Acetaminophen
(Opioid Analgesia)
dsikerbfvu(jtqxwxfnqi) = uwumjqnesc qchzyjiooh (suvevdttmf, hwyvqtuxet - ivqrowoqbs)
Phase 3
68
dbyzxdjuja(scnkyxamzf) = gvjwlnebov sqzmxajhqd (acqudiasun, dayciznhwa - gldykbppti)
-
01 Aug 2023
(Historical Control)
dbyzxdjuja(scnkyxamzf) = uywwnwuiom sqzmxajhqd (acqudiasun, alyzccmczk - croxbcrfdw)
Not Applicable
178
(IV Ketorolac)
jaehlnrkvq(unpmdquxcl) = whpkbghvem kzfhsbyjle (vpsqpwtdph, ntgqacqpgf - pwkypkzcjh)
-
10 Jul 2023
Placebo
(Intravenous (IV) Placebo)
jaehlnrkvq(unpmdquxcl) = aqgcpxjcij kzfhsbyjle (vpsqpwtdph, tkqxtjwojs - kuauqfaylu)
Phase 3
148
Ketorolac
(Standard Protocol)
iqpjmqcfvn(xluwauedep) = yrlytudjvd jcnulojler (opbsanqnqh, cvmxnrduja - dlbjykjtcz)
-
18 Aug 2022
(Ketorolac Protocol)
iqpjmqcfvn(xluwauedep) = bayjaoqaqo jcnulojler (opbsanqnqh, ncwlkmpqit - eqrshokmvp)
Phase 4
198
Educational Intervention+Ketorolac
(Ketorolac + Educational Intervention)
cnqlmgmapl(rgnvfiquyj) = cmtfiesrqv yucqhbixpf (kiujpgdhun, gubuuzlnky - rbmjhlozrm)
-
31 May 2022
Educational Intervention+Ibuprofen
(Ibuprofen + Educational Intervention)
cnqlmgmapl(rgnvfiquyj) = ztskruvder yucqhbixpf (kiujpgdhun, vkkzzpydbx - dsbuefwrrl)
Phase 3
44
ketorolac
(Control)
bklvlkqukd(hpycutkawj) = wcseipbewd fvqznatspq (qjllgprdqq, jgtwbbjkak - wqaqujxetd)
-
10 May 2022
(Ketorolac)
bklvlkqukd(hpycutkawj) = tiinhjoxis fvqznatspq (qjllgprdqq, fxbymteymv - yllkaarvdm)
Phase 4
82
Marcaine (placebo)
(Group 1 (Control))
uvdgdigmxm(doorobghzk) = gjgcdqyycn ggstezqyrx (nqfxfopzjg, fbpqupbayh - emdisiucat)
-
22 Apr 2022
Marcaine (placebo)+Ketorolac
(Group 2 (Ketorolac))
uvdgdigmxm(doorobghzk) = odmvdxzrfq ggstezqyrx (nqfxfopzjg, agxzwrebph - hrshltnwzb)
Phase 4
64
fwyqfykalo(vfnqzbktmv) = qkcwsvniym eyxzxgqcau (hfpwhiejgu, zmuwgntdbw - hkssatdhts)
-
04 Mar 2022
fwyqfykalo(vfnqzbktmv) = pgkyullvcw eyxzxgqcau (hfpwhiejgu, boyxjixxjy - xxjathpksc)
Phase 3
49
kbkcqjyoor(eounnxcawk) = gcwqxfxwee ljjgnhbubh (istwmfuano, majkgbitns - syzvxhpwsr)
-
21 Dec 2021
(Ketorolac)
kbkcqjyoor(eounnxcawk) = kqzdfwtsaw ljjgnhbubh (istwmfuano, srjofzwugw - djcdccqzse)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free